

# ForPatients

by Roche

Non-Small Cell Lung Cancer (NSCLC)

## A Study of MTIG7192A in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

**Trial Status**

Active, not recruiting

**Trial Runs In**

6 Countries

**Trial Identifier**

NCT03563716 2018-000280-81  
GO40290

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

### *Trial Summary:*

This study will evaluate the safety and efficacy of tiragolumab plus atezolizumab compared with placebo plus atezolizumab in chemotherapy-naïve patients with locally advanced unresectable or metastatic PD-L1-selected non-small cell lung cancer (NSCLC), excluding patients with a sensitizing EGFR mutation or ALK translocation.

**Genentech, Inc.**

Sponsor

**Phase 2**

Phase

**NCT03563716 2018-000280-81 GO40290**

Trial Identifiers

### *Eligibility Criteria:*

**Gender**

All

**Age**

>= 18 Years

**Healthy Volunteers**

No